Combined PD-1, BRAF and MEK inhibition in BRAF^V600E colorectal cancer: a phase 2 trial.

ABSTRACT: While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF^V600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with BRAF^V600E CRC. The primary end point was overall response rate, and the secondary end points were progression-free survival, disease control rate, duration of response and overall survival. The study met its primary end point with a confirmed response rate (24.3% in all patients; 25% in microsatellite stable pati

SUBMITTER: Tian J 

PROVIDER: S-EPMC9941044 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature